Effects of Febuxostat combined with Atorvastatin calcium in treatment of hyperlipidemia and hyperuricemia
Objective:To observe effects of Febuxostat combined with Atorvastatin calcium in treatment of patients with hyperlipidemia and hyperuricemia.Methods:A prospective study was conducted on 120 patients with hyperlipidemia and hyperuricemia admitted to the hospital from February 2020 to March 2023.According to the random number table method,they were divided into control group and observation group,60 cases in each group.The control group was treated with Atorvastatin calcium,while the observation group was treated with Febuxostat on the basis of that of the control group.The clinical efficacy,the blood lipid indexes[total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C)]levels,the serum uric acid level,the vascular endothelial function indexes[soluble intercellular adhesion molecule-1(sICAM-1),endothelin-1(ET-1)]levels before and after the treatment,and the incidence of adverse reactions during treatment were compared between the two groups.Results:The total effective rate of the observation group was 93.33%(56/60),which was higher than 80.00%(48/60)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of TG,TC,LDL-C and uric acid in the observation group were lower than those in the control group,the level of HDL-C was higher than that in the control group,and the differences were statistically significant(P<0.05).The levels of sICAM-1 and ET-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Febuxostat combined with Atorvastatin calcium in the treatment of the patients with hyperlipidemia and hyperuricemia can improve the total effective rate of treatment,improve the levels of blood lipid indexes,and reduce the levels of serum uric acid and vascular endothelial function indexes.Moreover,it is superior to single Atorvastatin calcium treatment.
万方数据
维普
